Source: PR-Inside

Press Release: Amgen : Molecular Partners Reports Key Financials for FY 2018 and Corporate

(PR-inside.com) Research & Development: MP0310: Molecular Partners and Amgen announced strategic collaboration for clinical development and commercialization of lead IO candidate MP0310 (FAP x 4-1BB), validating the company's immuno-oncology toolbox and DARPin® platform; first-in-human trial planned for H2 2019 MP0250 and MP0274: Additional patient data of ongoing phase 2 trial of MP0250 in combination with Velcade® in MM support data observed in first patient cohort; Complementary phase 2 trial of MP0250 in combination with Pomalyst® (IMiD) in MM in preparation; Recruitment of first patient cohort for phase 1 trial of MP0274 completed Abicipar (Allergan partnership): Phase 3 secondary endpoint data presented in Q4 2018 underline potential to become first fixed ..

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Amgen's latest SEC filings

Annual Revenue

Based on data from Amgen's latest SEC filings

Employees

Robert A. Bradway's photo - Chairman & CEO of Amgen

Chairman & CEO

Robert A. Bradway

CEO Approval Rating

69/100

Amgen discovers, develops, manufactures and delivers human therapeutics for patients suffering from serious illnesses.

Am...
Read more